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The purpose of this study was to evaluate whether tumour response to primary chemotherapy in human breast cancer is influenced
by baseline haemoglobin (Hb) status. A total of 157 patients with T2-4, N0-1 M0 breast cancer were treated with chemotherapy
consisting of either the CMF regimen þ tamoxifen (the first 76 cases) or the single-agent epirubicin (the subsequent 81) before
definitive surgery. In total, 144 patients were fully assessable. Ki67, p53, bcl-2, c-erbB2, steroid hormone receptor, and microvessel
density were evaluated immunohistochemically in tumour specimens obtained before chemotherapy and at surgery. Tumour
shrinkage 450% occurred in 72.1% of patients. Responding patients had higher baseline Hb levels and red blood cell counts than
nonresponders (Po0.01 and o0.003, respectively). The distribution of disease response according to increasing cutoffs of baseline
Hb status showed that from 12.5mgl
 1 onwards, patients with Hb levels above the cutoff obtained a greater response rate than
those with lower Hb values. The difference attained the statistical significance at 12.5 (76.1 vs 59.5%, Po0.05) and 13.0g/dl
 1 (81.0 vs
57.6%, Po0.002) cutoffs, respectively. The predictive role of Hb levels was maintained in multivariate analysis after adjustment for
clinical and biological characteristics and treatment regimen. Patients with baseline Hb levels p13gdl
 1 showed a lower treatment-
induced reduction in Ki67 expression (Po0.04) and a higher Ki67 expression at postoperative evaluation (Po0.02) than their
counterparts. In conclusion, low Hb levels may negatively influence the response rate of chemotherapy in breast cancer patients.
Inhibition of antiproliferative activity could be a possible mechanism.
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Tumour hypoxia has been shown to play an important role in the
outcome of cancer patients. Low intratumoural oxygen levels may
select for a more malignant phenotype (Coleman et al, 2001;
Feldmann, 2001; Hockel and Vaupel, 2001) and provoke tumour
aggressiveness, with a greater likelihood of malignant progression
and decreased responsiveness to standard therapy (Coleman et al,
2001; Feldmann, 2001; Hockel and Vaupel, 2001; Wouters et al,
2002).
Hypoxia is able to promote tumour metastasis by inducing the
expression of gene products involved in the metastatic cascade
(Graham et al, 1999; Xu et al, 1999; Canning et al, 2001), and by
stimulating neoangiogenesis (Semenza, 2001). Also, hypoxia may
mediate a selection pressure for a more aggressive phenotype by
promoting the clonal expansion of cells with diminished apoptotic
potential (Graeber et al, 1996).
Traditionally, Tumour hypoxia is considered a potential
therapeutic problem since it renders solid tumours more resistant
to radiation therapy (Feldmann, 2001; Hockel and Vaupel, 2001).
Moreover, under hypoxic conditions, the fraction of proliferating
tumour cells has been found to decrease, thus compromising the
effectiveness of most chemotherapeutic drugs that are primarily
effective against rapidly dividing cells (Eisenhauer et al, 1997;
Green and Giaccia, 1998).
The oxygenation status of human tumours is mainly dependent
on (1) the availability of oxygen via the blood, and (2) the
diffusional flux from the microvessel to the oxygen-consuming
cell. While oxygen availability process is a function of haemoglo-
bin (Hb) blood concentration, diffusional flux depends mainly on
the pO2 gradient and on the diffusion distance between vessels and
tumour cells (Coleman et al, 2001; Feldmann, 2001; Hockel and
Vaupel, 2001; Wouters et al, 2002).
Haemoglobin concentration has been shown to be an important
predictive factor for the outcome of radiotherapy or chemo-
radiotherapy in the treatment of various types of cancer, including
uterine – cervix cancer (Fyles et al, 1998), head and neck cancer
(Glaser et al, 2001) and bronchogenic carcinoma (Kovacs et al
1998). Data on the predictive role of Hb on disease response to
chemotherapy are lacking.
Preoperative chemotherapy administered to breast cancer
patients is the best model to identify baseline features able to
predict which patients may be most likely to benefit or not
from cytotoxic treatment (Bonadonna et al, 1998; Mamounas
and Fisher, 2001). This treatment modality allows a perfectly
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lquantifiable evaluation of the chemosensitivity or chemoresistance
of any treated case. In addition, tumour specimen biopsy obtained
in matched pair cases at diagnosis and definitive surgery can
provide valuable information on treatment-induced changes in
tumour biology (Fisher and Mamounas, 1995; Bottini et al, 2000).
In this study, we evaluated baseline Hb levels as a predictive
factor for response to treatment in a consecutive series of breast
cancer patients receiving primary chemotherapy in a single
institution.
The primary aim of the study was to investigate the effect of
baseline Hb values on tumour shrinkage induced by the treatment.
Secondary aims were: (1) to correlate Hb values with biological
parameters and (2) to correlate Hb values with changes in Ki67
expression before and after treatment.
PATIENTS AND METHODS
Patients
From August 1990 to January 1997, 157 consecutive patients with
an operable breast tumour or locally advanced disease (T2-4, N0-1,
M0) had been enrolled in two consecutive phase II studies that
tested the activity of the CMF regimen (cyclophosphamide,
methotrexate, 5-fluorouracil) combined with tamoxifen and the
activity of the single-agent epirubicin. None of the patients had
objective skin inflammation or Oedema. On first presentation, an
incision biopsy was performed on each patient. Initial staging
comprised clinical examination, bilateral mammography, echo-
graphy, chest X-ray, liver echography or CT scan, bone
scintigraphy. The study was approved by the institutional
Investigations Committee. All patients gave written informed
consent to the diagnostic procedures and the proposed
treatment.
Treatment
Chemotherapy was started within 1 or 2 days from diagnosis. The
first consecutive 76 patients received the CMF chemotherapy
regimen, which was given on days 1 and 8 every 28 days. The dose
of cyclophosphamide and 5-fluorouracil was 600mgm
 2 of body
surface area, and the dose of methotrexate was 40mgm
 2. The
subsequent 81 patients received epirubicin 60mgm
 2 on days 1
and 2 every 21 days. The first consecutive 45 patients with
oestrogen-positive (ERþ) breast cancer at first biopsy received
additional tamoxifen (TAM) (30mg daily) in association with the
CMF treatment. Each month, the size of the primary tumour and
the size of the axillary lymph nodes, when appreciable, were
carefully measured with a caliper by the same clinician. Response
was assessed by clinical measurement of the changes in the
product of the two largest diameters recorded in two successive
evaluations. Based on World Health Organization (WHO) criteria
(Miller et al, 1981), tumour progression (PD) was defined as an
increase of at least 25% in tumour size, stable disease (SD) as an
increase of less than 25% or a reduction of less than 50%, partial
response (PR) as a tumour shrinkage greater than 50%, and
complete response (CR) as the complete disappearance of all
clinical signs of disease.
Surgery was planned after full clinical reassessment about 1
month after the end of the last chemotherapy cycle. Quadrantect-
omy or modified radical mastectomy was performed when
indicated in association with full axillary dissection. All patients
subjected to quadrantectomy underwent irradiation of the residual
breast (60Gy delivered over 6 weeks). Before and during
chemotherapy, blood cell count was repeatedly evaluated; only
those evaluations performed a few days before incisional biopsy
and immediately before definite surgery were considered in the
present analysis.
Histopathologic grade and immunohistochemistry
The degree of malignancy was assessed according to the Elston and
Ellis (1991) grading system. The immunohistochemical methodol-
ogy used in this study is fully described elsewhere (Bottini et al,
2000). Briefly, an antigen-retrieval step was performed by heating a
tissue section in a citrate buffer. The primary antibodies applied
were: CD34/QB-END (mouse monoclonal (Novocastra Lab, New-
castle upon Tyne, UK), dilution 1:25, overnight incubation at
41C); ER (mouse monoclonal 6F11 (Novocastra Lab), dilution
1:50, 1h incubation at room temperature (RT); PgR (mouse
monoclonal 1A6 (Novocastra Lab), dilution 1:20, 1h incubation at
RT); Ki67 (mouse monoclonal Mib-1 (Dako, Glostrup, Denmark),
dilution 1:30, 1h incubation at RT); p53 (mouse monoclonal D07
(Novocastra Lab), dilution 1:100, 1h incubation at RT); bcl-2
(mouse monoclonal 124 (Dako), dilution 1:40, overnight at 41C);
and (c-erbB2 (mouse monoclonal CB11 (Novocastra Lab), over-
night at 41C).
Biotinylated horse anti-mouse IgG and avidin–biotin–perox-
idase complex were applied as a staining method (Vectastatin ABC
kit; Vector Laboratories, Inc., Burlingame, CA, USA). A solution
containing hydrogen peroxide (0.06% vv
 1) and diamino-benzi-
dine 4 HCl (DAB; 0.05 vv
 1) was used as chromogen.
Immunohistochemical scoring
All samples had a negative control slide (no primary antibody) of
an adjacent section to assess the degree of nonspecific staining.
Positive controls included breast carcinomas known to exhibit
high levels of each marker.
Staining was scored by counting the number of positive-stained
cells and expressed as a percentage of the total tumour cells (at
least 1000) counted across several representative fields of the
section using a standard light microscope equipped with a 10 10
square graticule. Reproducibility of counting was assessed by a
second investigator rescoring 10 slides.
Vascularity was defined as previously described (Bottini et al,
2002) as the number of vessels per field counted in the area of
highest vascular density (‘hot spots’) at  400 magnification. This
corresponded to a field size of 0.43mm
2. Five fields per tumour
section were counted in the areas that appeared to contain the
greatest number of microvessels. The average of counts in these
fields was considered in the analysis. All figures in the text are
quoted per mm
2.
The relative intensity of ER and PgR staining was assessed in a
semiquantitative manner, as previously described by McCarty et al
(1985), incorporating both the intensity and distribution of
specific staining. A value (HSCORE) was derived from the sum
of the percentages of positive-stained epithelial cells multiplied by
the weighted intensity of staining. Specimens were deemed
receptor positive if the HSCORE was greater than 100. For the
other biological parameters, a cutoff of X5 positive cells was
introduced to discriminate p53-positive and p53-negative primary
malignancies, as previously reported (Silvestrini et al, 1993). A
cutoff of 10% stained cells was considered for c-erbB2 positivity.
No cutoffs were introduced for bcl2 expression. The immunohis-
tochemical evaluation at definitive surgery was performed by the
same pathologists who remained blinded to the disease response
and the score assessed at first biopsy.
Statistical analysis
Parametric and nonparametric statistical methods (Student’s t-test
for paired and unpaired data, Mann–Whitney U-test for unpaired
data, and r for simple correlation analysis) were used, when
indicated, in the primary analyses of the data. The association
between dichotomous variables was assessed by w
2. Multivariate
analysis was performed by logistic regression. Relapse-free
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diagnosis to the occurrence of relapse of disease or disease-related
death. The OS and RFS curves were estimated using the Kaplan–
Meier method. Unadjusted differences in these estimates between
treatment groups were assessed with the log-rank test. Statistical
analysis was performed on an IBM-compatible personal computer
using the Statistica for Windows (Tulsa, OK, USA) software
package (Statsoft Inc., 1995).
RESULTS
One patient refused to continue the treatment plan at the end of
the first cycle. Two patients with baseline Hb level of 8gdl
 1 were
excluded from the study because they were bearing thalassemia
minor. In total, 154 patients were therefore fully evaluable and
included in the analysis. A median of three chemotherapy cycles
was administered (range 3–5). Patient characteristics, treatment
outcome and changes in immunohistochemical markers in the
present series are described elsewhere (Bottini et al, 2000, 2001,
2002). Briefly, according to WHO criteria (Miller et al, 1981), 38
patients attained a clinical CR, 73 a PR, for an overall response rate
of 72.1%. In all, 40 patients showed disease stabilization and three
progressed. Three patients obtained a complete pathological
response to treatment. Median Hb levels and red blood cell count
(RBC) (range) were 13.5gdl
 1 (10.7–16.3) and 4.5 10
6ml (3.5–
6.0) at baseline and 10.8gdl
 1 (7.2–14.5) and 3.5 10
6ml (2.4–
5.4) before definitive surgery (Po0.001). There was a moderate
correlation between baseline Hb and Hb evaluated before surgery
(Spearman r¼0.40, Po0.05). A similar relationship was observed
for RBC (r¼0.51, Po0.05). The decrease in Hb levels from
baseline was greater in the subset of patients treated with the
single-agent epirubicin than in the subgroup that received the CMF
regimen (Table 1).
Haemoglobin levels and treatment outcome
Haemoglobin and RBC at baseline condition in the 111 patients
attaining a disease response (median 13.7gdl
 1. (range 10.7–16.3)
and 4.56 10
6ml (3.7–6.0)) were higher than in those who did not
(median 12.8gdl
 1 (range 11.2–16.0) and 4.29 10
6ml (3.5–5.2));
Po0.01 and o0.003, respectively.
The distribution of disease response according to increasing
cutoffs of baseline Hb status is outlined in Table 2. From
12.5mgl
 1 onwards, patients with Hb levels above the cutoff
obtained a greater response rate than those with lower Hb values.
This difference attained statistical significance at 12.5 (P¼0.05)
and 13.0gdl
 1 (Po0.002). The cutoff of 13.0gdl
 1 was used for
subsequent statistical computations. Accordingly, 95 patients had
Hb values 413gdl
 1 and 59 had Hb values o13gdl
 1 on
baseline conditions, while the corresponding distribution of
patients at the end of treatment was 12 and 142, respectively. All
complete pathological responses were obtained in patients with Hb
values 413gdl
 1.
The predictive role of Hb status was more evident in the subset
submitted to epirubicin than in the CMF-treated subgroup. In the
latter group, only a trend (not significant) of greater response rate
was observed in favour of baseline Hb 413gdl
 1 (Figure 1).
In the multivariate analysis, Hb levels (considered as continuous
variable) showed a significant independent role in predicting
disease response after adjustment for menopausal status, T, N, c-
erbB2, p53, bcl-2, ER, PgR, CD 34, Ki67, and treatment
administered (Table 3).
At the last follow-up examination in May 2002, 44 patients
(28.6%) progressed and 39 (25.3%) died, the median follow-up of
surviving patients was 90 months (range 31–142). No difference in
disease-free interval (median 130 months vs not attained,
respectively) and overall survival (median not attained) was
observed between the patients with baseline Hbo13gdl
 1 and
those with baseline Hb 413gdl
 1.
Relationship between Hb levels and patients and tumour
characteristics
The variation in baseline Hb levels according to patient and
tumour characteristics are depicted in Table 4. Haemoblobin levels
were significantly greater in postmenopausal patients than in
premenopausal ones. No difference in Hb levels was observed
stratifying patients according to tumour size, lymph-node
involvement, tumour grade, steroid hormone receptor status, c-
erbB2, p53, bcl2, and Ki67 expression.
No relationship was found between MVD and Hb values at
baseline (Figure 2); a very low relationship was found when
considering Hb values and MVD at the end of treatment
(Spearman r¼ 0.24, Po0.05).
Table 5 describes the changes in Ki67 expression before and
after primary chemotherapy as well as the treatment-induced Ki67
variation, when patients were stratified according to baseline Hb
status. The pretreatment Ki67 labelling index was the same for
patients with low Hb levels and those with normal/high values.
However, patients with Hb levels 413gdl
 1 showed a greater
reduction in treatment-induced Ki67 expression and a lower Ki67
expression at postoperative evaluation than patients with Hb
o13gdl
 1.
Table 1 Haemoglobin (Hb) values before and after treatment according
to cytotoxic drug administration
CMF7tamoxifen Epirubicin
Baseline Hb
Mean (s.d.) 13.6 (1.11) 13.2 (1.0)
Median (range) 13.9 (10.7–16.0) 13.1 (10.9–16.3)
Reduction Hb
Mean (s.d.)  2.03 (1.30)  3.13 (1.27)
Median (range)  1.80 ( 5.3–0.7)  3.10 ( 6.3– 0.3)
Postchemotherapy Hb
Mean (s.d.) 11.6 (1.28) 10.1 (1.10)
Median (range) 11.5 (8.4–14.5) 10.1 (7.2–11.8)
CMF¼cyclophosphamide, methotrexate, 5-fluorouracil; s.d.¼standard deviation.
Table 2 Disease response to primary chemotherapy according to progressively higher cutoff of baseline haemoglobin (Hb) levels
Hb cutoffs mgdl
 1 12.0 12.5 13.0 13.5 14.0
Response rates
Hbpthe cutoff 9/12 (75.0%) 22/37 (59.5%) 34/59 (57.6%) 51/78 (65.4%) 77/112 (68.7%)
Hb4the cutoff 102/142 (71.8%) 89/117 (76.1%) 77/95 (81.0%) 60/76 (78.9%) 34/42 (80.9%)
P ¼0.8 ¼0.05 o0.002 ¼0.06 ¼0.1
Haemoglobin levels and chemotherapy activity
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In this single institution experience involving a relatively large
number of patients with operable breast cancer, baseline Hb levels
significantly influenced the tumour response to primary che-
motherapy. This predictive role was also maintained after
adjustment for disease stage, treatment, menopausal status, and
several tumour characteristics in multivariate analysis.
The logistic regression analysis revealed that c-erbB2 expression
was an independent predictor of overall disease response as well. c-
erbB2 overexpression has been found to correlate negatively with
the efficacy of CMF and TAM (but not the combination of these
drugs) (Hamilton and Piccart, 2000). Conversely, a positive
predictive value of c-erbB2 immunostaining has been found for
anthracycline-based chemotherapy (Ravdin, 2001). The adminis-
tration of epirubicin in more than half of our patients could
account for the results obtained.
Anaemia is a common finding in cancer patients (Caro et al,
2001). This can be related to the disease process itself or its
treatment, chemotherapy in particular (Groopman and Itri, 1999).
In our series, however, the tumour itself was not the major cause of
low Hb levels at baseline condition. Patients included in the study
were substantially healthy females bearing relatively small primary
tumours without metastatic disease. As shown in Table 4, Hb levels
were significantly lower in premenopausal patients than in
postmenopausal ones, suggesting that relative iron deficiency
related to the menstrual cycle represented the most important
mechanism. At surgery, the majority of patients had mild to
moderate anaemia subsequent to chemotherapy. The moderate
relationship between pre- and post-treatment Hb values suggests
0
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Hb >13 g dl–1; Hb13 g dl–1
P = 0.1 P < 0.02
CMF + TAM Epirubicin
Figure 1 Distribution of disease response by baseline Hb status and
treatment.
Table 3 Independent role of haemoglobin (Hb) in predicting disease
response to chemotherapy according to multivariate logistic regression
analysis
Hazard ratio 95% Confidence
intervals
P
T
a 0.71 0.46–1.10 0.12
Node status
a 1.08 0.49–2.37 0.84
p53
a 0.70 0.27–1.83 0.47
Bcl-2
a 1.24 0.41–3.73 0.70
Grading
a 1.56 0.69–3.52 0.28
Ki67
a 0.79 0.44–1.44 0.45
PgR
a 0.72 0.31–1.67 0.44
ER
a 1.03 0.28–3.70 0.96
Menopause
a 1.20 0.53–2.73 0.65
Treatment 0.56 0.26–1.21 0.14
c-erbB2
a 2.58 0.93–7.16 0.05
Hb level
b 1.48 1.03–2.11 0.03
aThese variables were categorised as displayed in Table 4.
bHaemoglobin level was
introduced as a continuous variable.
Table 4 Patient and tumour characteristics according to pretreatment
haemoglobin (Hb) levels
Hb mean s.d. P
Premenopausal 13.0 1.05 o0.01
Menopausal 13.6 1.02
T2 tumours 13.4 1.13 n.s.
T3-4 tumours 13.6 0.89
Node negative 13.4 1.13 n.s.
Node positive 13.4 1.00
Grading 2 13.6 1.14 n.s.
Grading 3 13.4 1.03
ER negative 13.4 1.16 n.s.
ER positive 13.4 1.05
PgR negative 13.5 1.14 n.s.
PgR positive 13.4 1.03
p53 negative 13.4 1.07 n.s.
p53 positive 13.5 1.06
c-erbB2 negative 13.3 0.97 n.s.
c-erbB2 positive 13.6 1.25
bcl2 negative 13.5 1.09 n.s.
bcl2 positive 13.4 1.07
Ki67p10 13.5 1.13
Ki67 11–29 13.3 1.01 n.s.
Ki67 X30 13.7 1.12
ER¼oestrogen receptor; n.s.¼not significant.
Regression
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Figure 2 Relationship between intratumoral MVD and Hb values before
chemotherapy.
Haemoglobin levels and chemotherapy activity
A Bottini et al
980
British Journal of Cancer (2003) 89(6), 977–982 & 2003 Cancer Research UK
C
l
i
n
i
c
a
lthat postchemotherapy Hb is influenced by pretreatment values.
As expected, the reduction in Hb was greater in the patient subset
treated with epirubicin than in that treated with CMF. When
patients were divided according to treatment regimen, the impact
of Hb on disease response was greater in the subset treated with
epirubicin than in the subgroup receiving CMF. Hypoxia-induced
resistance of tumour cells to anthracyclines has been repeatedly
described in vitro (Ikeda et al, 1999; Matthews et al, 2001). The
generation under normal oxygenation of reactive oxygen species
such as hydrogen peroxide and nitric oxide, which cause oxidative
damage to cellular proteins and apoptosis, could be a possible
mechanism (Ikeda et al, 1999; Matthews et al, 2001). In addition, in
the absence of oxygen, P450 reductase interacts with anthracy-
clines, leading to cleavage of the anthracycline glycosidic bond and
producing a molecule with no antitumour activity (Pan et al,
1981). In the CMF-treated group, most patients also received TAM
concomitantly, which could have counterbalanced the cytotoxic
resistance induced by hypoxia at least in part since the drug
induces apoptosis that is ER mediated (Dorssers et al, 2001) and
may not be influenced by tumour oxygenation.
It has been demonstrated that the oxygenation status of human
tumours is independent of clinical tumour size stage and grade
(Wouters et al, 2002). Our data agree with these findings; indeed,
no relationship was found between Hb levels and these tumour
characteristics. A wealth of laboratory data implicates hypoxia as a
contributor to the malignant phenotype (Hockel and Vaupel,
2001). Our data did not show a relationship between Hb levels and
either steroid receptor immunostaining or oncogene expression at
baseline condition.
Tumour hypoxia has been found to stimulate tumour-induced
neoangiogenesis (Hockel and Vaupel, 2001). Our data failed to
demonstrate a relationship between Hb levels and the MVD.
However, MVD is neither a measure of angiogenesis (Vermeulen
et al, 2002) nor does it reflect the degree of perfusion of a tumour
(Stohrer et al, 2000). Hence, the question of whether tumour
hypoxia induced by low Hb values may contribute to the
multifactorial stimulation of tumour-related neoangiogenesis
could not be addressed by our study.
At least two mechanisms have been identified as being
potentially responsible for chemotherapy resistance in anaemic
patients, that is, the loss of apoptotic potential and the inhibition
of cell proliferation. In this study, the apoptotic index was not
measured; instead, proliferation activity was assessed by the
expression of the Ki67 antigen. At baseline condition, no difference
in the percent of Ki67-stained cells according to Hb status was
found. After chemotherapy, however, reduction in Ki67 expression
was greater in the patient subgroup with baseline Hb values
413gdl
 1 than in their counterparts, which produced lower KI67
immunostaining in postchemotherapy residual tumours. These
data suggest that the antiproliferative activity of cytotoxic
treatment is promoted by tumour oxygenation.
Residual tumour is, by implication, resistant to chemotherapy.
Accordingly, our observation of greater Ki67 expression in the
postoperative specimens of patients with low Hb levels may
indicate the persistence of aggressive disease, with a higher risk of
disease relapse.
No difference between disease-free survival and overall survival
according to Hb status was observed, as the study was not powered
enough to search for these differences. Interestingly, anaemia was
found to have a negative predictive role for local RFS in a recent
study involving 424 premenopausal patients receiving adjuvant
chemotherapy (Sevelda and Gnant, 2002).
In conclusion, the study findings suggest that reduced Hb levels
with resulting poorer tumour oxygenation could be implicated in
the complex mechanisms of chemotherapy resistance of breast
cancer. Whether treatment resistance in anaemic patients can be,
at least partially, prevented or overcome by anaemia correction is a
matter for further investigation.
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